<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>METROLOTION - metronidazole lotion </strong><br>Galderma Laboratories, L.P.<br></p></div>
<h1>MetroLotion®<br>(metronidazole lotion)<br>Topical Lotion, 0.75%<br><br>Rx Only<br><br>For Topical Use Only<br>(NOT FOR OPHTHALMIC USE)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="ID_04E27C30-9168-CB87-932A-35E0B472288E"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="ID_F7BD01CB-59B1-E91B-2215-DE1FE5BE68E0"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">MetroLotion<span class="Sup">®</span> (metronidazole lotion) Topical Lotion contains metronidazole, USP, at a concentration of 7.5 mg per gram (0.75% w/w) in a lotion consisting of benzyl alcohol, carbomer 941, cyclomethicone, glycerin, glyceryl stearate, light mineral oil, PEG-100 stearate, polyethylene glycol 400, potassium sorbate, purified water, steareth-21, stearyl alcohol, and sodium hydroxide and/or lactic acid to adjust pH.</p>
<p>Metronidazole is an imidazole and is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is 2-methyl-5-nitro-1<span class="Italics">H</span>-imidazole-1-ethanol. The molecular formula is C<span class="Sub">6</span>H<span class="Sub">9</span>N<span class="Sub">3</span>O<span class="Sub">3</span> and molecular weight is 171.16. Metronidazole is represented by the following structural formula:</p>
<div class="Figure"><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c4e07c26-245d-3e51-6a47-fccde22334d2&amp;name=structuralformula.jpg"></div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="ID_F6CBF0EB-F965-6D96-EC69-6C1FA394B483"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">The mechanisms by which metronidazole acts in the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> are unknown, but appear to include an anti-inflammatory effect.</p>
<p><span class="Bold"><span class="Italics">Pharmacokinetics:</span></span> Absorption of metronidazole after topical application of MetroLotion<span class="Sup">®</span> Topical Lotion is lass complete and more prolonged than after oral administration. Detectable plasma levels were found in all subjects following the administration of a 1 gram dose of MetroLotion<span class="Sup">®</span> Topical Lotion (containing 7.5 mg of metronidazole) applied every morning and evening for 4 days to the faces of 8 patients. The highest concentration (96 ng/mL) seen following the morning dose on Day 5 was approximately 80 times lower than the peak concentrations produced by a single 250 mg tablet of metronidazole. The mean (± SD) AUC<span class="Sub">0-24</span> after twice daily administration was 962 ± 373 ng.hr/mL.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="ID_04D601DC-7E29-E5F3-1A0C-68E4A7116E1C"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">MetroLotion<span class="Sup">®</span> Topical Lotion is indicated for topical application in the treatment of inflammatory <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_5A97E6F6-7F99-FA08-D6FB-C4D5DBE3CC2D"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">A controlled clinical study was conducted in 144 patients with moderate to severe <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>, in which MetroLotion<span class="Sup">®</span> Topical Lotion was compared with its vehicle. Applications were made twice daily for 12 weeks during which patients were instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages, and caffeine. Patients were also provided samples of a soapless cleansing lotion and, if requested, a moisturizer. MetroLotion<span class="Sup">®</span> Topical Lotion was significantly more effective than its vehicle in mean percent reduction of inflammatory lesions associated with <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> and in the investigators’ global assessment of improvement. The results of the mean percent reduction in inflammatory lesion counts from baseline after 12 weeks of treatment and the investigators’ global assessment of improvement at week 12 are presented in the following table:</p>
<table border="0" cellpadding="4" width="90%">
<colgroup>
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
<col width="12.5%">
</colgroup>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule" align="center" colspan="8"><span class="Bold">Efficacy Outcomes at Week 12</span></td></tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="8"><span class="Bold">Mean Percent Reduction in Inflammatory Lesion Counts from Baseline</span></td></tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="4">MetroLotion<span class="Sup">®</span>   Topical Lotion<br>N=65</td>
<td class="Botrule Lrule Rrule" align="center" colspan="4">Vehicle Lotion<br>N=60</td>
</tr>
<tr>
<td class="Botrule Lrule" align="center" colspan="4">55%</td>
<td class="Botrule Lrule Rrule" align="center" colspan="4">20%</td>
</tr>
<tr><td class="Botrule Lrule Rrule" align="center" colspan="8"><span class="Bold">Investigators' Global Assessment of Improvement<br>(percent change from baseline)</span></td></tr>
<tr>
<td class="Botrule Lrule">  </td>
<td class="Botrule"> </td>
<td class="Botrule Lrule" align="center">Worse</td>
<td class="Botrule Lrule" align="center">No<br>Change</td>
<td class="Botrule Lrule" align="center">Minimal<br>Improvement</td>
<td class="Botrule Lrule" align="center">Definite<br>Improvement</td>
<td class="Botrule Lrule" align="center">Marked<br>Improvement</td>
<td class="Botrule Lrule Rrule" align="center">Clear</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" colspan="2">          MetroLotion<span class="Sup">®</span>    <br>          Topical Lotion<br>          N=65 </td>
<td class="Botrule Lrule" align="center">5%</td>
<td class="Botrule Lrule" align="center">12%</td>
<td class="Botrule Lrule" align="center">11%</td>
<td class="Botrule Lrule" align="center">32%</td>
<td class="Botrule Lrule" align="center">32%</td>
<td class="Botrule Lrule Rrule" align="center">8%</td>
</tr>
<tr>
<td class="Botrule Lrule" align="left" colspan="2">          Vehicle Lotion<br>          N=60 </td>
<td class="Botrule Lrule" align="center">15%</td>
<td class="Botrule Lrule" align="center">27%</td>
<td class="Botrule Lrule" align="center">23%</td>
<td class="Botrule Lrule" align="center">15%</td>
<td class="Botrule Lrule" align="center">20%</td>
<td class="Botrule Lrule Rrule" align="center">0%</td>
</tr>
<tr><td colspan="8"> </td></tr>
<tr><td colspan="8">The scale is based on the following definitions:</td></tr>
<tr>
<td colspan="2">Worse:</td>
<td colspan="6">Exacerbation of either <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> or quantitative<br>assessment of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>.</td>
</tr>
<tr>
<td colspan="2">No Change:</td>
<td colspan="6">Condition remains the same.</td>
</tr>
<tr>
<td colspan="2">Minimal Improvement:</td>
<td colspan="6">Slight improvement in the quantitative assessment<br>of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, and/or slight improvement <br>in <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</td>
</tr>
<tr>
<td colspan="2">Definite Improvement:</td>
<td colspan="6">More pronounced improvement in the quantitative<br>assessment of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, and/or<br>more pronounced improvement in <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</td>
</tr>
<tr>
<td colspan="2">Marked Improvement:</td>
<td colspan="6">Obvious improvement in the quantitative assessment<br>of <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> and/or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span>, and/or obvious<br>improvement in <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</td>
</tr>
<tr class="Last">
<td colspan="2">Clear</td>
<td colspan="6">No <span class="product-label-link" type="condition" conceptid="4105835" conceptname="Papule">papules</span> or <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> and minimal residual or no<br><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>.</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="ID_784C9B64-ADF8-0CDF-708B-50000CC0B861"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">MetroLotion<span class="Sup">®</span> Topical Lotion is contraindicated in individuals with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to metronidazole or to other ingredients of the formulation.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="ID_5B5B9693-BA6E-2AB5-B3E2-44C75DE95E30"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"><span class="Italics"><span class="Bold">General:</span></span> Topical metronidazole formulations have been reported to cause tearing of the eyes. Therefore, contact with the eyes should be avoided. If a reaction suggesting local irritation occurs, patients should be directed to use the medication less frequently or discontinue use. Metronidazole is a nitroimidazole and should be used with care in patients with evidence or history of <span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">blood dyscrasia</span>.</p>
<p><span class="Bold"><span class="Italics">Information for Patients:</span></span> Patients using MetroLotion<span class="Sup">®</span> Topical Lotion should receive the following information and instructions:</p>
<ol>
<li>This medication is to be used only as directed by the physician.</li>
<li>It is for external use only.</li>
<li>Avoid contact with the eyes.</li>
<li>Cleanse affected area(s) before applying this medication.</li>
<li>Patients should report any adverse reaction to their physician.</li>
</ol>
<p><span class="Bold"><span class="Italics">Drug Interactions:</span></span> Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and coumarin anticoagulants, resulting in a prolongation of <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time. The effect of topical metronidazole on <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time is not known.</p>
<p><span class="Bold"><span class="Italics">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></span> Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic, oral administration in mice and rats. Metronidazole has not been assessed for carcinogenic activity following topical administration. In several long term studies in mice, oral doses of approximately 200 mg/m<span class="Sup">2</span>/day (approximately 20 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and following normalization of the data on the basis of the body surface area)) or greater were associated with increase incidences of lung tumors in male mice and <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphomas</span> in female mice. In several long-term studies in rats, oral administration of metronidazole resulted in increased incidences of mammary and hepatic tumors in female rats and testicular tumors and <span class="product-label-link" type="condition" conceptid="437251" conceptname="Benign neoplasm of pituitary gland and craniopharyngeal duct">pituitary adenomas</span> in male rats at dosages of approximately 1600 mg/m<span class="Sup">2</span>/day (approximately 170 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and following normalization of the data on the basis of the body surface area)) or greater. In another oral study, an increase of mammary tumors was observed in female rats that received approximately 160 mg/m<span class="Sup">2</span>/day (approximately 17 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and the following normalization of the data on the basis of the body surface area)).</p>
<p>Ultraviolet radiation-induced carcinogenesis was enhanced in albino mice by intraperitoneal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> of metronidazole at a dosage of 45 mg/m<span class="Sup">2</span>/day, 5 days per week for 10 weeks, as indicated by a decreased latency period to the development of skin neoplasms. It is unclear how this level of exposure compares to the clinical situation with respect to the concentration of the drug or metabolics in the skin. This study did not determine if metronidazole must be present during exposure to ultraviolet radiation in order to enhance tumor formation; metronidazole may promote tumor formation in cells that have previously been initiated by ultraviolet radiation.</p>
<p>Metronidazole exhibited mutagenic activity in several <span class="Italics">in vitro</span> bacterial and mammalian assay systems. Intraperitoneal administration of metronidazole to mice resulted in a dosage-dependent increase in the incidence of chromosomal aberrations in peripheral <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> was reported in patients with Crohn`s disease who were treated with metronidazole for 1 to 24 months at a dosage of 200 to 1200 mg/day. However, similar results were not observed in another study, in which humans were treated for 8 months.</p>
<p>In rats, oral metronidazole at a dosage of approximately 1800 mg/m<span class="Sup">2</span>/day (approximately 200 times the exposure of a patient that received the estimated maximum human topical daily dose (assuming 100% bioavailability and following normalization of the data on the basis of body surface area)) induced inhibition of spermatogenesis and severe testicular degeneration.</p>
<p><span class="Bold"><span class="Italics">Pregnancy: </span></span><span class="Italics">Teratogenic Effects: </span><span class="Italics">Pregnancy Category B:</span> There are no adequate and well-controlled studies with the use of MetroLotion<span class="Sup">®</span> Topical Lotion in pregnant women. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity was observed after oral administration of metronidazole in rats or mice. However, because animal reproduction studies are not always predictive of human response and since oral metronidazole has been shown to be a carcinogen in some rodents, this drug should be used during pregnancy only if clearly needed.</p>
<p><span class="Italics"><span class="Bold">Nursing Mothers:</span></span>  After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels are significantly lower with topically applied metronidazole than those achieved after oral administration of metronidazole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
<p><span class="Italics"><span class="Bold">Pediatric Use:</span></span>  Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_718C07B2-E4BA-977D-D37A-A344AC668DB1"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In a controlled clinical trial, safety data from 141 patients who used MetroLotion<span class="Sup">®</span> Topical Lotion (n=71), or the lotion vehicle (n=70), twice daily and experienced a local cutaneous adverse event which may or may not have been related to the treatments include: local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, MetroLotion<span class="Sup">®</span> Topical Lotion 2 (3%), lotion vehicle 0; <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, MetroLotion<span class="Sup">®</span> Topical Lotion 2 (3%), lotion vehicle 1 (1%); <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, MetroLotion<span class="Sup">®</span> Topical Lotion 1 (1%), lotion vehicle 0; skin <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span> (burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>), MetroLotion<span class="Sup">®</span> Topical Lotion 1 (1%), lotion vehicle 2 (3%); <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, MetroLotion<span class="Sup">®</span> Topical Lotion 4 (6%), lotion vehicle 0; <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>, MetroLotion<span class="Sup">®</span> Topical Lotion 0, lotion vehicle 1 (l%); and worsening of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span>, MetroLotion<span class="Sup">®</span> Topical Lotion 1 (1%), lotion vehicle 7 (10%).</p>
<p>The following additional adverse experiences have been reported with the topical use of metronidazole: <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, transient <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, metallic taste, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness of extremities</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="ID_2D577DC1-C0EE-81F9-3AC5-BDD068B14101"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply a thin layer to entire affected areas after washing. Use morning and evening or as directed by physician. Avoid application close to the eyes.</p>
<p>Patients may use cosmetics after waiting for the MetroLotion<span class="Sup">®</span> Topical Lotion to dry (not less than 5 minutes).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_A47E7317-8DA3-A641-FEF7-2EE08E6CBD14"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">MetroLotion<span class="Sup">®</span> (metronidazole lotion) Topical Lotion, 0.75% is supplied in the following size:</p>
<p>2 fl. oz. (59 mL) plastic bottle - <span class="Bold">NDC</span>0299-3838-02</p>
<p><span class="Bold"><span class="Italics">Storage:</span></span>  Store at controlled room temperature 68° to 77°F (20° - 25°C).</p>
<p>Protect from freezing.</p>
<p>Marketed by:<br>GALDERMA LABORATORIES, L.P.<br>Fort Worth, Texas 76177 USA<br>Manufactured by:<br>DPT Laboratories, Ltd.<br>San Antonio, Texas 78215 USA<br>GALDERMA is a registered trademark.<br><span class="Bold">325066-0704</span>          Revised: July 2004</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_27EB5320-E6B7-B99C-1FF8-42C500345E10"></a><a name="section-10"></a><p></p>
<h1>PACKAGE LABEL</h1>
<div class="Figure"><img alt="Front Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c4e07c26-245d-3e51-6a47-fccde22334d2&amp;name=frontlabel.jpg"></div>
<p class="First"><span class="Bold">Rx Only</span></p>
<p><span class="Bold">NDC </span>0299-3838-02</p>
<p>MetroLotion<span class="Sup">®</span><br>(metronidazole lotion)</p>
<p><span class="Bold">Topical Lotion</span></p>
<p><span class="Bold">0.75%</span></p>
<p>2 FL OZ<br>(59 mL)</p>
<p><span class="Bold">GALDERMA</span></p>
<div class="Figure"><img alt="Back Labels" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=c4e07c26-245d-3e51-6a47-fccde22334d2&amp;name=backlabels.jpg"></div>
<p>For Topical Use Only.</p>
<p>Not for Ophthalmic Use.</p>
<p>Store at controlled room temperature 68º to 77ºF (20º – 25ºC).</p>
<p>Protect from freezing.</p>
<p><span class="Bold">Usual dosage:</span> Apply a thin layer to entire affected areas after washing. Use morning and evening or as directed by physician. Avoid application close to the eyes.</p>
<p><span class="Bold">Each Gram Contains:<br></span>Active: metronidazole, 0.75% w/w (7.5 mg).<br>Inactive: benzyl alcohol, carbomer 941, cyclomethicone, glycerin, glyceryl stearate, light mineral oil, PEG-100 stearate, polyethylene glycol 400, potassium sorbate, purified water, steareth-21, stearyl alcohol, and sodium hydroxide and/or lactic acid to adjust pH.</p>
<p>See lot no. and expiration date on bottom of bottle.</p>
<p>Marketed by:<br>GALDERMA LABORATORIES, L.P.<br>Fort Worth, Texas 76177 USA<br>GALDERMA is a registered trademark.<br>Manufactured by:<br>DPT Laboratories, Ltd.<br>San Antonio, Texas 78215 USA</p>
<p>326250-1209</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>METROLOTION  		
					</strong><br><span class="contentTableReg">metronidazole lotion</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0299-3838</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Metronidazole</strong> (Metronidazole) </td>
<td class="formItem">Metronidazole</td>
<td class="formItem">7.5 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Benzyl Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Carbomer Homopolymer Type A</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Cyclomethicone</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Glyceryl Monostearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Light Mineral Oil</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Polyoxyl 100 Stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Polyethylene Glycol 400</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Potassium Sorbate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Steareth-21</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Stearyl Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Lactic Acid</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0299-3838-02</td>
<td class="formItem">59.7 g in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020901</td>
<td class="formItem">11/24/1998</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Galderma Laboratories, L.P.
							(047350186)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">DPT Laboratories, Ltd.</td>
<td class="formItem"></td>
<td class="formItem">832224526</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 7/2004<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>12ebabb0-074a-ca50-13ec-0c6ebca9d1d9</div>
<div>Set id: c4e07c26-245d-3e51-6a47-fccde22334d2</div>
<div>Version: 1</div>
<div>Effective Time: 20040725</div>
</div>
</div> <div class="DistributorName">Galderma Laboratories, L.P.</div></p>
</body></html>
